Akili News

Shareholder Alert: Ademi LLP Investigates Whether Akili, Inc. Has Obtained a Fair Price for Its Public Shareholders

MILWAUKEE, May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutic

PR NewswireMay 29 12:17 ET

Akili Announces Merger Agreement and Recommends Shareholder Approval

TipRanksMay 29 09:42 ET

Express News | Trading Halt: Halt Status Updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

BenzingaMay 29 08:25 ET

Express News | PureTech Health Announces Merger Agreement Between Akili and Virtual Therapeutics to Form Leading Digital Health Company

BenzingaMay 29 08:11 ET

Express News | Akili Inc: Following Completion of Transaction, Combined Organization Will Operate as Virtual Therapeutics

ReutersMay 29 08:01 ET

Express News | Akili Inc: Akili to Operate as Wholly Owned Subsidiary of Virtual Therapeutics

ReutersMay 29 08:00 ET

Express News | Akili Inc: Upon Completion of Transaction, Akili's Common Stock Will No Longer Be Listed on Any Public Stock Exchange.

ReutersMay 29 08:00 ET

Express News | Akili Inc: Akili Shareholders Will Receive $0.4340 per Share of Common Stock in Cash

ReutersMay 29 08:00 ET

Express News | Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company

ReutersMay 29 08:00 ET

Press Release: Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company

Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company Akili to operate as wholly owned subsidiary of Virtual Therapeutics KIRKLAN

Dow JonesMay 29 08:00 ET

Express News | Trading Halt: Halted at 7:57:37 A.m. ET - Trading Halt: Halt News Pending

BenzingaMay 29 07:57 ET

Akili Q1 2024 Adj EPS $(0.12) Beats $(0.14) Estimate, Sales $383.00K Miss $794.00K Estimate

Akili (NASDAQ:AKLI) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 29.41 percent increase over losses of $(0.17) per sh

BenzingaMay 14 16:41 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersArcutis Biotherapeutics (NASDAQ:ARQT) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1

BenzingaMay 14 16:31 ET

Express News | Akili Evaluates Potential Strategic Alternatives

BenzingaMay 14 16:24 ET

Akili | 10-Q: Quarterly report

SEC announcementMay 14 16:24 ET · Announcements

Akili 1Q Rev $383,000 >AKLI

Akili 1Q Rev $383,000 >AKLI

Dow JonesMay 14 16:05 ET

Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, Vs. Street Est of $0.8M

04:03 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M

MT NewswiresMay 14 16:03 ET

Express News | Akili Inc: Will Not Provide Financial Guidance Until Further Notice

ReutersMay 14 16:02 ET

Express News | Akili Inc: Evaluating Potential Strategic Alternatives

ReutersMay 14 16:02 ET

Express News | Akili Inc: Full Voluntary Prepayment of Debt and Termination of Amended & Restated Loan and Security Agreement With Silicon Valley Bank

ReutersMay 14 16:02 ET